key: cord-0804040-egpzi5p2
authors: Timbrook, Tristan T.; Hueth, Kyle D.; Ginocchio, Christine C.
title: Identification of Bacterial Co-Detections in COVID-19 Critically Ill Patients by BioFire® FilmArray® Pneumonia Panel: A Systematic Review and Meta-Analysis
date: 2021-07-01
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2021.115476
sha: fe53e815dc03efb94ea78f2984b47d3123d45160
doc_id: 804040
cord_uid: egpzi5p2

COVID-19 disease is associated with significant morbidity and mortality among patients admitted to the ICU. Bacterial coinfections may occur, and timely appropriate therapy may be limited with culture-based microbiology due to turnaround time and diagnostic yield challenges (e.g. antibiotic pre-exposure). We performed a systematic review and meta-analysis of the impact of BioFire® Pneumonia Panel in detecting bacteria and clinical management among critically ill COVID-19 patients admitted to the ICU. Seven studies with 558 patients were included. Antibiotic use before respiratory sampling occurred in 28-79% of cases. The panel incidence of detections was 33% (95% CI 0.25 to 0.41, I(2)=32%) while culture yielded 18% (95% CI 0.02 to 0.45; I(2)=93%). The panel was associated with approximately a 1 and 2 day decrease in turnaround for identification and common resistance targets, respectively. The panel may be an important tool for clinicians to improve antimicrobial use in critically ill COVID-19 patients.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a worldwide pandemic beginning in 2020. A recent meta-analysis has reflected all-cause mortality is 10% for hospitalized patients with coronavirus disease 2019 (COVID-19) but 34% among patients admitted to the intensive care unit (ICU) [1] . Guidelines for the management of critically ill patients on mechanical ventilation with COVID-19 have recommended the empiric use of antimicrobials [2] . Concerns over bacterial coinfections have led to significant antimicrobial use with an estimated up to 80% of critically ill COVID-19 patients receiving antimicrobial therapy [3] .

A recent meta-analysis on bacterial coinfections among COVID-19 patients has reported incidence of up to 15% for coinfections among patients with secondary bacterial infections, almost universally from studies utilizing culture-based methods [4] . These methods are known to be insensitive, often due to a variety of factors including antibiotic exposure before specimens are obtained, poor quality samples, variation in plate growth interpretation, and the challenges associated with cultivating fastidious organisms [5, 6] . The role of culture-independent techniques in the management of severe COVID-19 patients has been suggested as a potential avenue towards improving judicious therapy decisions and antimicrobial stewardship [7] . The BioFire ® FilmArray ® Pneumonia/Pneumonia plus Panels (BioFire PN/PNplus; BioFire Diagnostics, LLC, Salt Lake City, UT) are molecular multiplex PCR tests that allow for increased sensitivity of detecting causative etiologies of pneumonia and related resistance gene determinates [8] . The panels include 15 common bacteria targets reported with semi-quantitative results (10 4 , 10 5 , 10 6 , ≥10 7 ), qualitative results for 3 atypical bacteria (Mycoplasma pneumoniae, Chlaymdia pneumoniae, and Legionella pneumophila), 7 genetic markers for antibiotic resistance (mecA/C and MREJ, bla CTX-M , bla KPC (1, 2, 3, 4) , respiratory syncytial virus). SARS-CoV-2 is not on the current version of the panel and is not cross-reactive to the panel's other coronaviruses. We performed a systematic review and meta-analysis to determine the incidence of bacterial co-detections using the BioFire PN/PNplus among critically ill patients with COVID-19.

We reviewed PubMed and Embase from January 1, 2020 to June 4, 2021 for studies in English evaluating the use of the BioFire PN/PNplus among COVID-19 patients. We searched using the query: (bioMérieux OR BioFire OR FilmArray) AND (pneumonia OR LRTI OR 'lower respiratory tract infection') AND (COVID OR COV OR SARS-COV-2 OR SARSCoV2 OR Coronavirus). We included clinical studies which reported the incidence of bacterial co-detections by the panel among COVID-19 patients admitted to the ICU. Additionally, we evaluated patient characteristics, epidemiology of bacterial and viral codetections, detections by culture, and antimicrobial use among these studies. Studies were excluded if data were insufficient to evaluate the contribution of PN/PNplus Panels on incidence of co-detections such as missing data or analyte only results given multiple bacterial results are common with the panels. References of selected articles were reviewed for identification of additional articles of relevance in addition to a forward citation search via Google Scholar. Eligibility assessment, data extraction, and quality assessments were completed by two investigators (T.T.T.) and (K.D.H.) with any discordance resolved by a third investigator (C.C.G.). Quality assessments were completed using JBI Checklist. [9] All meta-analyses were performed using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria) and included using 'meta' package [10] . Pooled incidence and 95% confidence intervals (CIs) for incidence of molecular bacterial co-detection in addition to non-culture based approaches were assessed using random-effect model with weights as described by DerSimonian and Laird [11] . Random effects modeling was employed on the assumption of heterogeneity among study characteristics. Heterogeneity was evaluated using I 2 and Cochran's Q test. For heterogeneity testing, results were considered significant with a p<.10 as the Q test has low power. Egger test was used to evaluate publication bias. The systematic review and meta-analysis was reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary Table 1 ).

The literature search resulted in 155 studies meeting our search criteria (Supplementary Figure 1) . Excluded studies were comprised of 12 duplicates studies, 96 non-PN/PNplus Panel studies, 18 review articles or position statements, 17 non-clinical or non-human studies, two commentaries, three non-SARS-CoV-2 study, and one study due to insufficient data for evaluating incidence of codetections related to PN Panel [12] . After removing duplicate and non-applicable studies, seven studies with 558 patients were included for the systematic review and meta-analyses (Table 1, Supplementary Table 2 ) [13] [14] [15] [16] [17] [18] [19] . Studies included a study from Belgium, Italy, and five studies from France occurring from January to December, 2020 and all used the PNplus panel version. Two studies had overlap of less than 10 patients (personal communication from Dr. Dauwalder) and thus both were included [14, 16, 20] .

All studies were solely among patients admitted to ICUs and having inclusion of respiratory specimens obtained at varying times during their ICU stay (e.g. at ICU admit, upon intubation, within 48h of intubation, etc.). Four studies reported on timing of specimen collection including two studies noting an average collection 1 and 5 days after ICU admission, one study reporting an average of 3 hours after intubation, and one study with 33% of PN Panel testing within 48 hours of ICU admission [15] [16] [17] 19] . Antibiotic use occurred in 28.1% to 79% of patients before respiratory specimens were obtained. One study reported on turnaround time (TAT) noting PNplus results having a significantly decreased median TAT compared to culture and antimicrobial susceptibility testing results, 5.5h vs 25.9h (p<.001) and 57h (p<.001), respectively [13] . Patients median age ranged from 57-68 years, and mortality was noted to range from 28-57% across studies.

The pooled incidence of co-detections by BioFire PNplus per patient was 33% (95% CI 0.25 to 0.41, I 2 =32%, Cochran's Q p=.22, Egger's test p=.34; Figure 1 ) [13] [14] [15] [16] . In contrast, culture-based detections yielded a pooled incidence of 18% (95% CI 0.02 to 0.45; I 2 =93%, Cochran's Q p<.01, Egger's test p=.87; Supplementary Figure 2 ) [13, 14, 16] . Two additional PNplus Panel studies only reported co-detections per specimen, indicating many patients had multiple specimens collected, and noted 33% and 40% bacterial co-detections, respectively [18, 19] . Finally, one study did not report out bacterial co-detection attributed specifically to PNplus Panel per patient or per specimen, but noted overall 28% co-detections by either culture or PNplus Panel [17] .

Bacteria detected by PNplus Panel among all evaluated specimens resulted in 302 positive organism results for non-atypical bacteria among six studies [13] [14] [15] [17] [18] [19] . One study was excluded as individual organisms could not specifically be delineated to the PNplus Panel [16] . PNplus Panel detected typical bacteria including Enterobacterales (n=83, 27.5%), Staphylococcus aureus (n=69, 22.8%), Pseudomonas aeruginosa (n=66, 21.9%), Haemophilus influenzae (n=36, 11.9%), Acinetobacter calcoaceticus-baumannii complex (n=20, 6.6%), Streptococcus pneumoniae (n=15, 5.0%), Moraxella catarrhalis (n=6, 2.0%), Streptococcus agalactiae (n=4, 1.3%), and Streptococcus pyogenes (n=3, 1.0%). Atypical bacteria were detected in two studies reflecting M. pneumoniae and L. pneumophila [14, 18] . Viral results were noted in two studies which reported a human rhinovirus/enterovirus and an adenovirus [14, 19] . Isolates with resistant gene detection were noted in 4 of 7 studies, including bla CTX-M extended-spectrum β-lactamases (ESBLs), bla NDM and bla VIM carbapenemase, and S. aureus methicillin-resistance genes [13-15, 18, 19] .

Antibiotic therapy was reported in 6/7 (85.7%) of studies [13] [14] [15] [17] [18] [19] . The majority of therapy used included 3 rd generation cephalosporin or narrower therapies. Two studies reported the clinical impact on antibiotic decision making [15, 19] . In one study, the PNplus Panel was associated with early therapy changes in 34% (38/112) episodes [19] . For negative results, 43% of cases allowed for antibiotic avoidance or discontinuation while the remainder of cases maintained therapy due to severe sepsis, infection from another site, continuation of previous treatment, or severely immunocompromised patients. The other study noted early antibiotic modifications occurred in 46.9% (14/32) of patients, of which 35.7% (5/14) of patients on initial therapy had their antibiotics stopped due to a negative result [15] .

In this systematic review and meta-analysis of seven studies and 558 patients, the BioFire PNplus was associated with 33% codetections among critically ill COVID-19 patients, nearly double the detections by culture and higher than previously reported in COVID-19 culture-focused meta-analyses [3, 21] . Moreover, our review reflects a differing epidemiology of organisms that culture focused reviews with the molecular approach reporting predominantly Enterobacterales, S. aureus, and P. aeruginosa. A recent commentary by Rawson et al highlighted the disparities of current studies, including patient populations, disease severity and, importantly, diagnostic methods. This clearly highlights more systematic, comprehensive testing is needed to accurately define the composition, extent, and role of co-infections in COVID-19 disease [22] . Interestingly, our results corroborate findings in a comprehensive review of postmortem studies of bacterial superinfections among persons with COVID-19 reflecting 32% of potential bacterial superinfections based on histology [23] .

As diagnostic uncertainty is a known major driver of antibiotic use, the use of molecular diagnostics among critically ill COVID-19 patients has the potential to improve management [24] . The relevance of this diagnostic approach is further highlighted from the included studies reflecting earlier antimicrobial streamlining in 34-47% of patients including 36-43% of antibiotics discontinued or avoided due to a negative result [15, 19] . The importance of streamlining appropriate antimicrobial management is paramount with the high rates of antimicrobial use and mortality of up to 34% among these critically ill ICU admitted COVID-19 patients [1] .

In addition to the importance of appropriate therapy at the patient level, there is significance for the overall state of increasing antimicrobial resistance globally. A recent review found despite only 8% of COVID-19 patients having a bacterial or fungal coinfection during hospitalization, up to 72% are reported to have received antimicrobial therapy overall and up to 100% when in the ICU [21, 25] . Similarly, the studies in our review reported antibiotic use in up to 79% of patients. The World Health Organization has emphasized the importance of antimicrobial stewardship in the pandemic response by identifying 5 key measures, among them rapid diagnostics that differentiate between bacterial and viral respiratory tract infections [26] . Diagnostic platforms like the BioFire PN/PNplus can play an important role in reducing the antimicrobial prescribing behaviors that have developed during the COVID-19 pandemic and the potential subsequent lasting effects well into the future.

While the improved diagnostic yield of BioFire PN/PNplus among COVID-19 patients is recent in the literature, many studies have reflected this broadly among pneumonia patients. A recent study evaluating the diagnostic yield of the panel versus a pneumonia multi-test bundle determined the panel was twice as likely to yield determination of the bacterial etiology for community-acquired pneumonia (CAP) while costing $60 less per case for testing [27] . Moreover, in a multinational evaluation among 52 laboratories, the BioFire PNplus was associated with a 20% increase in detections of one of more pathogens per specimen compared to standard of care testing [28] . The increase in diagnostic yield is likely multifactorial. For instance in one study, increased detections with the panel were shown to be likely related to previous antibiotic exposure and culture reporting process in 49% and 42% of cases, respectively [29] . The variation based on culture reporting process is further suggested by our data as the heterogeneity among BioFire PNplus detections was much lower than culture (I 2 32% vs 93%). In another study, the clinical relevance of increased detections was recently explored, reflecting strong positive correlations to level of WBC on gram stain thus indicating a correlation of inflammation with these detections [30] . Finally, the increased sensitivity over culture has been demonstrated in a European multicenter study of the BioFire PNplus, the Curetis ® Unyvero ® Pneumonia Panel, and 16S metagenomic analysis which reflected consistency in detections among molecular platforms as being more sensitive than culture [31] . Evidence reflecting the improved pathogen detection of molecular methods for pneumonia has previously been reported elsewhere [32] .

As indicated in previous meta-analyses on COVID-19 coinfections, the present analysis is limited as some detections among the included studies may represent colonization [3] . However, the BioFire PN/PNplus may assist in this adjudication of infection vs colonization through semi-quantitative results. Several studies have examined the utility of using the panel's semi-quantitative values to assist in the differentiation of bacterial colonization versus infection [28, 29, [33] [34] [35] . Interpretation can be variable depending on several factors, including patient population, type of pneumonia (e.g. CAP versus ventilator associated pneumonia), sample type (sputum-like versus bronchoalveolar lavage-like), presence and amounts of other pathogens, WBC counts and adjunctive biomarkers. Although in general the panel's values tend to be one or more logs greater than conventional culture values, relative pathogen abundances can assist in determining pathogen significance similar to culture interpretation [28, 29, [33] [34] [35] . Thus, in conjunction with clinical judgment, the BioFire PN/PNplus can increase the diagnostic information available and rate of delivery to clinicians for earlier and more robust therapy decision making. While the panels detect common organisms and resistance targets, the results reported may be limited in generalizability depending on local organism and genotypic resistance epidemiology. Additionally, the results may be impacted by timing of specimen in the course of disease as noted in other reviews as classifying coinfection vs secondary infection is challenging [3] . Moreover, the observed results on therapy impact may be different in varying patient populations, severity of illness, and illness history as indicated among one of the studies noting more severe illness or immunocompromised states may challenge streamlining of therapy on a case-by-case basis. The results of our study are limited by regional representativeness of the included studies all originating in Europe. Variations of bacterial coinfections may be possible, and thus, our estimate of prevalence may lack generalizability. Future studies should evaluate molecular co-detections of bacteria among critically ill COVID-19 patients in additional regions. We included two studies which had overlap of less than 10 patients (personal communication from Dr. Dauwalder) which could add some bias to our estimates of prevalence but based on the proportion of overlap, overall increases available information for estimate [14, 16, 20] . Finally, studies had heterogeneity in the eligibility for inclusion and analysis which may have impacted the results.

In conclusion, our study reflects the increase of bacterial co-detections among critically ill COVID-19 ICU patients using the BioFire PN/PNplus Panels. Thus, overcoming the limitations of culture-based methods in terms of sensitivity and turnaround time, the BioFire PN/PNplus Panels may be an important tool to frontline clinicians for improving antimicrobial use in critically ill COVID-19 patients. 

Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Co-infections in people with COVID-19: a systematic review and meta-analysis

Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

COVID-19 and antimicrobial stewardship: What is the interplay?

Multicenter Evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus Panel for Detection and Quantification of Agents of Lower Respiratory Tract Infection

Checklist for Prevalence Studies

How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health

Meta-analysis in clinical trials

Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance

Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19

Assessment of Respiratory Bacterial Coinfections Among Severe Acute Respiratory Syndrome Coronavirus 2-Positive Patients Hospitalized in Intensive Care Units Using Conventional Culture and BioFire, FilmArray Pneumonia Panel Plus Assay. Open Forum Infect Dis

Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis

Early bacterial co-infection in ARDS related to COVID-19

Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU

Respiratory bacterial co-infections in intensive care unit-hospitalized COVID-19 patients: Conventional culture vs BioFire FilmArray pneumonia Plus panel

Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit

Methodology for Dealing With Duplicate Study Effects in a Meta-Analysis

Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing

Understanding the role of bacterial and fungal infection in COVID-19

Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. Open Forum Infect Dis

Factors Influencing Antibiotic-Prescribing Decisions Among Inpatient Physicians: A Qualitative Investigation

COVID-19, superinfections and antimicrobial development: What can we expect?

Tackling antimicrobial resistance in the COVID-19 pandemic

Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire(R) Pneumonia FilmArray(R) Panel

BioFire® FilmArray® Pneumonia plus Panel Performance Evaluation: A Multicenter, International Collaborative Study. Open Forum Infectious Diseases

Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections

Performance of a Semi-quantitative Multiplex Bacterial PCR Panel Compared with Standard Microbiological Laboratory Results: 396 Patients Studied with the BioFire® Pneumonia Panel

Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study. medRxiv

Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia

Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and the main determinants of resistance from the lower respiratory tract specimens of adult patients in intensive care units

Evaluation of the BioFire FilmArray Pneumonia Panel for rapid detection of respiratory bacterial pathogens and antibiotic resistance genes in sputum and endotracheal aspirate specimens

Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections

performed all reviews, data extractions, and quality assessments